ArticleAmerican journal of hematology2017
Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool.
Article in American journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Accuracy of the COMPASS-CAT thrombosis risk assessment scale in predicting venous thromboembolism in cancer patients: a meta-analysis.Journal of thrombosis and thrombolysis · 2024Pooled it
- Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis.Health technology assessment (Winchester, England) · 2024Pooled it
- Risk assessment models for venous thromboembolism in hospitalised adult patients: a systematic review.BMJ open · 2021Pooled it
- Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis.Blood advances · 2021Pooled it
- American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.Blood advances · 2021Guideline
- Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial.Blood advances · 2020Trial
- The COMPASS-CAT risk assessment model for predicting in-hospital venous thromboembolism in patients with breast, lung, colorectal, and ovarian cancer: A retrospective cohort study.The Journal of international medical research · 2026Article
- Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors.International journal of molecular sciences · 2026Review
- Development and validation of the CHI-CAT score: a novel tool for assessing cancer-associated venous thromboembolism risk in China.BMC cancer · 2025Article
- Preferences Among Expert Physicians in Areas of Uncertainty in Venous Thromboembolism Management: Results from a Multiple-Choice Questionnaire.Journal of clinical medicine · 2025Article
- A comprehensive review of venous thromboembolism risk assessment models for hospitalized medical patients: comparative evidence, implementation challenges, and future directions.Frontiers in cardiovascular medicine · 2025Review
- The effect of enhanced recovery after surgery on the risk factors of venous thromboembolism for patients with gynecologic malignancies.Frontiers in oncology · 2025Article
- Risk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies.Research and practice in thrombosis and haemostasis · 2025Article
- Advancing Thrombosis Research: A Novel Device for Measuring Clot Permeability.Sensors (Basel, Switzerland) · 2024Article
- Review
- Development and validation of machine learning models for postoperative venous thromboembolism prediction in colorectal cancer inpatients: a retrospective study.Journal of gastrointestinal oncology · 2023Article
- Development and validation of machine learning models for venous thromboembolism risk assessment at admission: a retrospective study.Frontiers in cardiovascular medicine · 2023Article
- Development and validation of a machine learning model to predict venous thromboembolism among hospitalized cancer patients.Asia-Pacific journal of oncology nursing · 2022Article
- Article
- Cancer-associated venous thromboembolism.Nature reviews. Disease primers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Inpatient venous thromboembolism (VTE) is a priority preventable illness; risk in cancer varies and prophylaxis is inconsistently used. A previously validated tool (Khorana Score, [KS]) identifies VTE risk in cancer outpatients with 5 easily available variables but has not been studied in the inpatient setting. We evaluated the validity of KS in predicting VTE risk in hospitalized cancer patients. We conducted a retrospective cohort study of consecutive oncology inpatients at the Cleveland Clinic from 11/2012 to 12/2014 (n = 3531). Patients were excluded for VTE on admission (n = 304), incomplete KS data (n = 439) or other reasons (n = 8). Data collected included demographics, cancer type, length of stay (LOS), anticoagulant use, and laboratory values. Multivariate risk factors were identified with stepwise logistic regression, confirmed with bootstrap analysis. Of 2780 patients included, 106 (3.8%) developed VTE during hospitalization. Median age was 62 (range, 19-98) years and 56% were male. Median LOS was 5 (range, 0-152) days. High risk KS (≥ 3) was significantly associated with VTE in uni- and multivariate analyses (OR 2.5, 95% [confidence interval] CI 1.3-4.9). Other significant variables included male gender (OR 1.67, 1.1-2.53), older age (OR 0.86, 0.75-0.99) and use of anticoagulants (OR 0.57, 0.39-0.85). Recursive partitioning analysis suggested optimal cut point for KS is 2 (OR 1.82, 1.23-2.69). This is the first report validating KS as a risk tool to predict VTE in hospitalized cancer patients. Using this tool could lead to more consistent and successful application of inpatient thromboprophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.